Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
A TACL Phase 1/2 Study of PO Ixazomib in combination with chemotherapy for childhood relapsed or refractory ALL and Lymphoblastic Lymphoma (Takeda)
Protocol ID
T2017-002
Disease (Sub Disease)
Leukaemia (ALL)
Diagnosis Stage
Relapsed/ refractory
Location
NSW, VIC
Sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Collaborators
Takeda
Children's Hospital Los Angeles
Children's Hospital Los Angeles
Links
Trial Status
Open
Sites
The Children's Hospital at Westmead
Sydney Children's Hospital
Royal Children's Hospital
Sydney Children's Hospital
Royal Children's Hospital
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
1 Year to 21 Years
International registry ID's
NCT03817320
| Study Title | A TACL Phase 1/2 Study of PO Ixazomib in combination with chemotherapy for childhood relapsed or refractory ALL and Lymphoblastic Lymphoma (Takeda) |
|---|---|
| Protocol ID | T2017-002 |
| Disease (Sub Disease) | Leukaemia (ALL) |
| Diagnosis Stage | Relapsed/ refractory |
| Location | NSW / VIC |
| Sponsor | Therapeutic Advances in Childhood Leukemia Consortium |
| Collaborators | Takeda/ Children's Hospital Los Angeles |
| Links | https://clinicaltrials.gov/ct2/show/NCT03817320 |
| Trial Status | Open |
| Trial Open Date | 12/02/2019 |
| Sites | The Children's Hospital at Westmead / Sydney Children's Hospital / Royal Children's Hospital |
| Study Type | Treatment |
| Phase | Phase 1/2 |
| Age Eligibility | 1 Year to 21 Years |
| International registry ID's | NCT03817320 |